FORA Capital LLC Acquires 62,553 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

FORA Capital LLC lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 81.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 139,139 shares of the company's stock after buying an additional 62,553 shares during the period. FORA Capital LLC owned approximately 0.06% of Hims & Hers Health worth $3,364,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership boosted its position in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the period. Vanguard Group Inc. boosted its position in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Yong Rong HK Asset Management Ltd acquired a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $41,104,000. Renaissance Technologies LLC increased its stake in shares of Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after acquiring an additional 1,562,302 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Hims & Hers Health by 613.9% during the 4th quarter. Invesco Ltd. now owns 1,277,026 shares of the company's stock worth $30,878,000 after acquiring an additional 1,098,148 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HIMS. Leerink Partners increased their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Canaccord Genuity Group raised their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Needham & Company LLC reaffirmed a "buy" rating and issued a $61.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, UBS Group reaffirmed a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Trading Up 12.5%

NYSE:HIMS traded up $6.88 on Tuesday, reaching $62.09. 58,983,927 shares of the stock traded hands, compared to its average volume of 18,680,671. The company's 50 day moving average is $33.25 and its 200-day moving average is $32.74. Hims & Hers Health, Inc. has a 1-year low of $12.07 and a 1-year high of $72.98. The firm has a market capitalization of $13.90 billion, a price-to-earnings ratio of 141.12 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same quarter last year, the firm posted $0.05 EPS. The company's quarterly revenue was up 110.7% on a year-over-year basis. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the transaction, the chief executive officer now directly owns 97,687 shares in the company, valued at $5,692,221.49. The trade was a 56.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Melissa Baird sold 33,333 shares of the firm's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $25.78, for a total value of $859,324.74. Following the transaction, the chief operating officer now directly owns 805,083 shares in the company, valued at approximately $20,755,039.74. This represents a 3.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 631,660 shares of company stock valued at $24,978,043 over the last 90 days. Insiders own 13.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.